Program Memorandum Intermediaries/Carriers: Autologous Stem Cell Transplantation (AuSCT) for Patients With Multiple Myeloma
Guidance that revises Medicare instructions in the Coverage Issues Manual, for autologous stem cell transplantation (AuSCT) with multiple myeloma patients, to state that effective October 1, 2000, single AuSCT is only covered for Durie-Salmon Stage II or III patients who fit the following requirements: newly diagnosed or responsive multiple myeloma; adequate cardiac, renal, pulmonary, and hepatic function.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: November 02, 2000
HHS is committed to making its websites and documents accessible to the widest possible audience, including individuals with disabilities. We are in the process of retroactively making some documents accessible. If you need assistance accessing an accessible version of this document, please reach out to the guidance@hhs.gov.
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.